Paricalcitol Articles
Abbott UK: "growth of 70% in next five years"
27 June 2005
Abbott files NDA for Zemplar capsules
9 August 2004
Abbott to study D-receptor activation in chronic kidney disease
24 November 2003
Tetrionics to Manufacture Paricalcitrol For Abbott's Zemplar
19 November 1998
Canadian Filing For One-Alpha D2
6 August 1998
Abbott's Paricalcitol Is Approved In The USA
30 April 1998
Showing 1-9 of 9 articles
- 1
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Is failure to adopt business process management putting the pharma industry at risk?
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
